Clinical remission is achieved in severe T2-high asthma after biological treatments, suggesting CRP as a predictive biomarker.
Biological treatments with omalizumab, mepolizumab or benralizumab are capable of inducing clinical remission at 12 months in around one third of severe T2-high asthmatics. A low baseline CRP might be predictive of achieving remission.
No takes yet. Share an insight, caveat, or question.
Vervier et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: